News and Trends 9 Dec 2022 New targeted drug shows benefit against breast cancer in first phase III trial A new type of targeted medicine has shown ‘remarkable’ benefits for patients with advanced breast cancer in a major phase III clinical trial. The drug capivasertib combined with hormone therapy doubled the time it took for cancer to progress in people with advanced forms of the most common type of breast cancer. The findings, presented […] December 9, 2022 - 7 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 9 Dec 2022 Ginkgo Bioworks launches Ginkgo Enzyme Services Ginkgo Bioworks has announced the launch of Ginkgo Enzyme Services. Ginkgo Enzyme Services is powered by ultra high throughput screening and machine learning-guided protein design, as well as optimized proprietary bacterial and fungal host strains. Ginkgo Enzyme Services solves challenges for R&D teams developing enzymes, from discovery of novel enzyme activity through optimization of enzyme […] December 9, 2022 - 2 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 9 Dec 2022Beyond Biotech podcast 25: Center for Global Development, Humacyte, Transgene This week, we have three interviews. One is from Bio-Europe, a chat with Transgene chief business officer, Steven Bloom, and we also have conversations with Humacyte CEO Laura Niklason, and with Anthony McDonnell, Senior Policy Analyst at the Center for Global Development, on the subject of antimicrobial resistance. We also have our weekly commentary from […] December 9, 2022 Share WhatsApp Twitter Linkedin Email
News and Trends 9 Dec 2022 The Native Antigen Company expands infectious disease portfolio The Native Antigen Company (part of LGC Clinical Diagnostics), today announced the commercial release of its Sudan Ebolavirus Boniface 1976 Glycoprotein (SEBOV GP). The addition of this latest recombinant protein expands the company’s comprehensive portfolio of antigens and antibodies for infectious diseases and has been designed to support immunoassay and vaccine development. The Native Antigen […] December 9, 2022 - 2 minutesmins - By Liza Laws Share WhatsApp Twitter Linkedin Email
News and Trends 8 Dec 2022 PDC*line Pharma presents first immunological results from trial with PDC*lung01 PDC*line Pharma, a clinical stage biotech company has announced the first immunological results of its PDC-LUNG-101 phase 1/2 clinical trial investigating PDC*Lung01. The company’s lead therapeutic is the off-the-shelf cancer vaccine candidate for non-small cell lung cancer (NSCLC). PDC*line Pharma develops potent and scalable active immunotherapies for cancers. The preliminary data was presented today at […] December 8, 2022 - 3 minutesmins - By Liza Laws Share WhatsApp Twitter Linkedin Email
More News! 8 Dec 2022 Enhertu’s positive results demonstrate improvement in overall survival Enhertu, an antibody drug conjugate, being jointly developed by Daiichi Sankyo and AstraZeneca, has demonstrated a statistically significant and clinically meaningful improvement in overall survival. Updated results from DESTINY-Breast03 phase 3 trial showed Enhertu (trastuzumab deruxtecan) was performing better than trastuzumab emtansine (T-DM1) in patients with HER2 positive unresectable and/or metastatic breast cancer previously treated […] December 8, 2022 - 4 minutesmins - By Liza Laws Share WhatsApp Twitter Linkedin Email
News and Trends 8 Dec 2022 MicrofluidX raises £3.3M to develop advanced therapy manufacturing platform MicrofluidX (MFX), a U.K. based provider of next-generation bioreactors for cell research and manufacturing, has announced £3.3 million ($4 million) of secured investments. This brings the company’s total funding to date to £7 million ($8.5 million). MicrofluidX’s next generation platform, the Cyto Engine, addresses the need for an affordable, scalable cell culture platform to revolutionize […] December 8, 2022 - 2 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 8 Dec 2022 MetrioPharm reveals COVID-19 study data MetrioPharm AG, a Swiss pharmaceutical company developing drugs for inflammatory diseases, has announced topline data from its CT05 phase IIa study of small molecule macrophage metabolic modulator MP1032 in COVID-19 patients. In the trial, patients received either MP1032 plus standard of care (SoC), or placebo plus SoC. SoC partially included other antivirals (Remdesivir or Nirmatrelvir/Ritonavir), […] December 8, 2022 - 4 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 8 Dec 2022 New method uses metabolism to detect cancers When cancer is detected at an early stage, the rates of survival increase drastically, but today only a few cancer types are screened for. An international study led by researchers from Chalmers University of Technology, Sweden, shows that a new, previously untested method can easily find multiple types of newly formed cancers at the same […] December 8, 2022 - 4 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 8 Dec 2022 Novadip bone healing trial yields positive results Novadip Biosciences SA has announced positive data from its phase 1/2 clinical trial evaluating the safety and clinical activity of its investigational product, NVD-003. The study was on patients with severe bone non-union (BNU) of the lower limb following trauma. Novadip is a clinical-stage biopharmaceutical company developing a new class of regenerative tissue products to […] December 8, 2022 - 5 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 8 Dec 2022 Laevoroc Oncology pushes for relapsed leukemia cure Laevoroc Oncology, a privately-owned, Swiss oncology development company, has announced the publication of key preclinical data carried out at the University of California, Los Angeles (UCLA), which provides mechanistic insights into the immunoregulatory functions of purine nucleoside phosphorylase (PNP) with Laevoroc’s PNP inhibitor, LR 09. The research shows that PNP is a novel metabolic immune […] December 8, 2022 - 2 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 8 Dec 2022 Sosei Heptares signs R&D agreements on gastrointestinal and immune disorders Sosei Heptares has entered translational medicine and R&D agreements with the MRC Weatherall Institute of Molecular Medicine at the University of Oxford, U.K., and KU Leuven, Belgium. Sosei Heptares focuses on G protein-coupled receptor (GPCR) focused structure-based drug design (SBDD) and development. The focus of the agreements is to apply the innovative technologies and research […] December 8, 2022 - 3 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email